Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
wet AMD
Biotech
Opthea scraps wet AMD program after eye drug loses to Lucentis
Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to can the entire wet AMD program.
James Waldron
Mar 31, 2025 6:55am
Opthea's eye disease drug defeated by Eylea in phase 3
Mar 24, 2025 5:24am
4DMT restructures pipeline, extending cash runway through 2028
Jan 10, 2025 2:00pm
Outlook's eye disease drug fails to match Lucentis, sinking stock
Nov 27, 2024 8:40am
Adverum's gene therapy reduces treatment burden in wet AMD
Feb 8, 2024 11:17am
4DMT links gene therapy to drop in Eylea injections
Feb 5, 2024 6:23am
